Literature DB >> 18438953

Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma.

J N Kloth1, A Gorter, G J Fleuren, J Oosting, S Uljee, N ter Haar, E J Dreef, G G Kenter, E S Jordanova.   

Abstract

In cervical cancer, an important mechanism by which tumour cells escape immune surveillance is loss of HLA class I, enabling tumours to evade recognition and lysis by cytotoxic T lymphocytes. Some tumours, however, escape from immune surveillance without accumulating defects in antigen presentation. We hypothesized that tumours with no or partial loss of HLA class I develop alternative mechanisms to prevent immune elimination. To investigate this hypothesis, genome-wide expression profiling using Illumina arrays was performed on cervical squamous cell carcinomas showing overall loss of HLA class I, partial, and normal HLA class I protein expression. Statistical analyses revealed no significant differences in gene expression between tumours with partial (n = 11) and normal HLA class I expression (n = 10). Comparison of tumours with normal/partial HLA class I expression (n = 21) with those with overall loss of HLA class I expression (n = 11) identified 150 differentially expressed genes. Most of these genes were involved in the defence response (n = 27) and, in particular, inflammatory and acute phase responses. Especially SerpinA1 and SerpinA3 were found to be up-regulated in HLA-positive tumours (3.6- and 8.2-fold, respectively), and this was confirmed by real-time PCR and immunohistochemistry. In a group of 117 tumours, high SerpinA1 and SerpinA3 expression in association with normal/partial HLA expression correlated significantly with poor overall survival (p = 0.035 and p = 0.05, respectively). Thus, HLA-positive tumours are characterized by higher expression of genes associated with an inflammatory profile. In addition, expression of the acute phase proteins SerpinA1 and SerpinA3 in HLA-positive tumours is associated with worse prognosis. Copyright (c) 2008 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438953     DOI: 10.1002/path.2347

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

1.  SERPINA3 Silencing Inhibits the Migration, Invasion, and Liver Metastasis of Colon Cancer Cells.

Authors:  Long-Lei Cao; Xu-Feng Pei; Xu Qiao; Jie Yu; Hui Ye; Chang-Lei Xi; Pei-Yun Wang; Zhi-Lin Gong
Journal:  Dig Dis Sci       Date:  2018-05-31       Impact factor: 3.199

2.  Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer.

Authors:  Marlies Schrevel; E Michelle Osse; Frans A Prins; J Baptist M Z Trimbos; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Int J Oncol       Date:  2017-05-03       Impact factor: 5.650

3.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

4.  Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method.

Authors:  Jia Zhao; Yu-Xia Fan; Yang Yang; Dong-Lei Liu; Kai Wu; Feng-Biao Wen; Chun-Yang Zhang; Deng-Yan Zhu; Song Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions.

Authors:  Ravindra Varma Polisetty; Poonam Gautam; Rakesh Sharma; H C Harsha; Sudha C Nair; Manoj Kumar Gupta; Megha S Uppin; Sundaram Challa; Aneel Kumar Puligopu; Praveen Ankathi; Aniruddh K Purohit; Giriraj R Chandak; Akhilesh Pandey; Ravi Sirdeshmukh
Journal:  Mol Cell Proteomics       Date:  2012-01-04       Impact factor: 5.911

6.  Proteomic identification of alpha-2-HS-glycoprotein as a plasma biomarker of hypopharyngeal squamous cell carcinoma.

Authors:  Wen-Dong Tian; Jun-Zheng Li; Shui-Wang Hu; Xiao-Wei Peng; Gang Li; Xiong Liu; Huai-Hong Chen; Xia Xu; Xiang-Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

7.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

8.  SERPINA3 promotes endometrial cancer cells growth by regulating G2/M cell cycle checkpoint and apoptosis.

Authors:  Guang-Dong Yang; Xiao-Mei Yang; Huan Lu; Yuan Ren; Ming-Ze Ma; Lin-Yan Zhu; Jing-Hao Wang; Wei-Wei Song; Wen-Ming Zhang; Rong Zhang; Zhi-Gang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

9.  Alpha-1-Antitrypsin Antagonizes Cisplatin-Induced Cytotoxicity in Prostate Cancer (PC3) and Melanoma Cancer (A375) Cell Lines.

Authors:  Mila Ljujic; Sanja Mijatovic; Mirna Z Bulatovic; Marija Mojic; Danijela Maksimovic-Ivanic; Dragica Radojkovic; Aleksandra Topic
Journal:  Pathol Oncol Res       Date:  2016-09-12       Impact factor: 3.201

10.  N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications.

Authors:  Ruth Hüttenhain; Silvia Surinova; Reto Ossola; Zhi Sun; David Campbell; Ferdinando Cerciello; Ralph Schiess; Damaris Bausch-Fluck; George Rosenberger; Jingchung Chen; Oliver Rinner; Ulrike Kusebauch; Marián Hajdúch; Robert L Moritz; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2013-02-13       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.